Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Enterprise Value (2020 - 2025)

Historic Enterprise Value for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$27.7 million.

  • Oncology Institute's Enterprise Value rose 4165.23% to -$27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year increase of 4165.23%. This contributed to the annual value of -$49.7 million for FY2024, which is 4005.31% up from last year.
  • Per Oncology Institute's latest filing, its Enterprise Value stood at -$27.7 million for Q3 2025, which was up 4165.23% from -$30.3 million recorded in Q2 2025.
  • Oncology Institute's 5-year Enterprise Value high stood at -$11.5 million for Q3 2021, and its period low was -$115.2 million during Q4 2021.
  • Moreover, its 5-year median value for Enterprise Value was -$49.7 million (2024), whereas its average is -$56.1 million.
  • As far as peak fluctuations go, Oncology Institute's Enterprise Value tumbled by 182020.67% in 2021, and later skyrocketed by 4577.17% in 2024.
  • Over the past 5 years, Oncology Institute's Enterprise Value (Quarter) stood at -$115.2 million in 2021, then soared by 35.92% to -$73.8 million in 2022, then dropped by 12.26% to -$82.9 million in 2023, then soared by 40.05% to -$49.7 million in 2024, then soared by 44.32% to -$27.7 million in 2025.
  • Its Enterprise Value was -$27.7 million in Q3 2025, compared to -$30.3 million in Q2 2025 and -$39.7 million in Q1 2025.